An innovative use of HSV-1 vectors lays the foundation for a novel genetic screen for modulators of ligand-gated ion channels.
References
Srinivasan, R. et al. Nat. Methods 4, 733–739 (2007).
Szallasi, A., Cortright, D.N., Blum, C.A. & Eid, S.R. Nat. Rev. Drug Discov. 6, 357–372 (2007).
Okuse, K. et al. Nature 417, 653–656 (2002).
Jegla, T. & Salkhoff, L. J. Neurosci. 17, 32–44 (1997).
Wang, Y. et al. Am. J. Physiol. Cell Physiol. 278, C619–C626 (2000).
Fink, D.J., DeLuca, N.A., Goins, W.F. & Glorioso, J.C. et al. Annu. Rev. Neurosci. 19, 265–287 (1996).
Burton, E.A. et al. Stem Cells 19, 358–377 (2001).
Yeomans, D.C. et al. Hum. Gene Ther. 16, 271–277 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
All of the authors work for the Neurogen Corporation, which is in the business of identifying novel drug therapies, some of which may target ion channels such as Trpv1.
Rights and permissions
About this article
Cite this article
Cortright, D., Buck, M. & Krause, J. Hunting for ion channel modulators with herpes simplex virus. Nat Methods 4, 692–693 (2007). https://doi.org/10.1038/nmeth0907-692
Issue Date:
DOI: https://doi.org/10.1038/nmeth0907-692
- Springer Nature America, Inc.
This article is cited by
-
TRPV4 channel is involved in HSV-2 infection in human vaginal epithelial cells through triggering Ca2+ oscillation
Acta Pharmacologica Sinica (2023)